Use of Daratumumab in Relapsed Refractory Multiple Myeloma and Clinical Experience

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-02-16
DOI
https://doi.org/10.5281/zenodo.18663727
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of Daratumumab in Relapsed Refractory Multiple Myeloma and Clinical Experience

Kübra Oral
Zenodo (CERN European Organization for Nuclear Research)
Multiple Myeloma Research and Treatments
article

Use of Daratumumab in Relapsed Refractory Multiple Myeloma and Clinical Experience

Kübra Oral
article en

Abstract

No abstract available for this paper.
Zenodo (CERN European Organization for Nuclear Research)
Fırat University (TR)
Openalex Percentile: Top 53%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Use of Daratumumab in Relapsed Refractory Multiple Myeloma and Clinical Experience — Kübra Oral · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS